Health plan startup Centivo raises $75M
Centivo, a startup that sells health insurance to employers, raised $75 million in fresh funds months after it bought a virtual primary care startup to use in its offerings. The startup’s goal is to...
View ArticleSanofi hires Mike Quigley as next chief scientist, internal memo says
Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma’s next chief scientific officer, Endpoints News has learned. Quigley will replace Frank...
View ArticleClik here to view.
Samsara adds three venture partners to help steer and advise portfolio companies
Biotech investment firm Samsara BioCapital has added three new venture partners in recent months to expand its network, support first-time CEOs in its portfolio and guide more companies by way of board...
View ArticleClik here to view.
Checking up on past Endpoints 11 winners: Who went public, who got bought and...
You win some, you lose some — that’s the risk of trying to predict the next hot biotechs. Since 2018, the Endpoints 11 awards have identified startups with the right ingredients to become a great drug...
View ArticlePCI Pharma earmarks $356M to expand injectable device capacity in US and Ireland
PCI Pharma Services is pouring $365 million to expand its US and Irish footprint for commercial and clinical packaging of drug-device products to meet “evolving” market needs. The CDMO, which...
View ArticleCapricor to begin filing DMD drug with FDA next month; Surrozen’s $10M milestone
Plus, news about Adaptimmune, Roche, LIfT BioSciences, VerImmune, and Revance Therapeutics: Capricor Therapeutics to file Duchenne cardiomyopathy treatment with the FDA: The San Diego-based biotech in...
View ArticleClik here to view.
Wave rides new Phase 2 DMD data as it sets sights on accelerated approval
Wave Life Sciences said new Phase 2 biomarker data for its exon-skipping therapy are promising for certain patients with Duchenne muscular dystrophy, and it plans to discuss accelerated approval plans...
View ArticleRegeneron hits setback in Eylea patent battle with Amgen
Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its blockbuster eye treatment Eylea. While Regeneron previously defended itself in...
View ArticleSIGA fires former NYC Covid advisor after secret recordings detail...
Biotech company SIGA Technologies has fired chief medical officer Jay Varma, days after the publication of secret recordings of the former New York City public health advisor talking about how he...
View ArticleNovo Nordisk CEO skeptical of PBM promises in Senate hearing on weight loss...
Sen. Bernie Sanders (I-VT) told Novo Nordisk CEO Lars Fruergaard Jørgensen that three major pharmacy benefit managers have agreed not to penalize the company for lowering the list prices of its popular...
View ArticleFDA adcomm will reexamine approval of checkpoint inhibitors in two cancers...
The FDA’s Oncologic Drugs Advisory Committee will meet Thursday to discuss whether several immune checkpoint inhibitor drugs should come with narrower indications in two cancers, based on emerging data...
View ArticleClik here to view.
Amgen reports dual Phase 3 wins in atopic dermatitis and myasthenia gravis
Amgen released data from two pivotal trials on Tuesday that showed its experimental drug rocatinlimab succeeded in a Phase 3 test in atopic dermatitis, while its approved drug Uplizna also yielded...
View ArticleClik here to view.
Italian gene therapy startup nabs $52M for rare genetic disease that Moderna...
Genespire patched together a €46.6 million (about $52 million) funding round to get its lead gene therapy into the clinic in a few years. The Milan-based biotech, which employs nine people, said...
View ArticleClik here to view.
2seventy bio, Bristol Myers end late-stage Abecma study in multiple myeloma
2seventy bio and its partner Bristol Myers Squibb said Wednesday that they are discontinuing enrollment in the Phase 3 KarMMa-9 study investigating Abecma in patients with newly diagnosed multiple...
View ArticleFDA OKs IntraBio's drug less than a week after rare disease's first-ever...
Within the span of a week, the FDA gave the green light to another drug for the rare condition Niemann-Pick disease type C in the form of IntraBio’s levacetylleucine. On Friday, the FDA approved Zevra...
View ArticleMerck's LAG-3 plus Keytruda combo fails Phase 3 in colorectal cancer
Merck’s efforts to combine its PD-1 blockbuster Keytruda with an experimental LAG-3 inhibitor hit a stumbling block Wednesday morning. The company said a Phase 3 study testing the LAG-3 program...
View ArticleSanofi inks deal with I-Mab; Wave discloses $175M offering on heels of DMD data
Plus, news about BioAge, Fulcrum Therapeutics and Arcutis Biotherapeutics: Sanofi snags Greater China rights to CD73 antibody: The French pharma will pay TJ Biopharma €32 million (or about $35 million)...
View Article#EADV24: Novo's semaglutide shows potential in chronic skin condition in...
A small study conducted by researchers at St. Vincent’s University Hospital in Dublin suggests that Novo Nordisk’s GLP-1 semaglutide could treat a common and chronic skin condition called hidradenitis...
View ArticleCelldex reveals Phase 2 responses for chronic hives drug and higher rates of...
Celldex Therapeutics has unveiled 52-week results from a mid-stage study of its anti-KIT drug in chronic hives, raising anticipation for ongoing registrational studies. But the company’s shares $CLDX...
View ArticleClik here to view.
Emergent says it has $400M in orders related to mpox outbreak
Emergent BioSolutions has secured around $400 million worth of orders for its smallpox and monkeypox products, including its vaccine being used to help protect against a mpox outbreak in Africa. The...
View Article